Phase i trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients

International Journal of Clinical Oncology

Volumn 18, Issue 3, 2013, Pages 510-516

  Frustaci, Sergio ^a   Buonadonna, Angela ^a   Turchet, Elisa ^a   Corona, Giuseppe ^a   Tabaro, Gianna ^a   Miolo, Gianmaria ^a   Torrisi, Elena ^a   Lo Re, Giovanni ^b   Tumolo, Salvatore ^b   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Chemotherapy; DOC regimen; Pharmacokinetic; Phase I

Indexed keywords

CAPECITABINE; CHLORPHENTERMINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; OXALIPLATIN; PREDNISONE; RANITIDINE; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANGINA PECTORIS; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; FRACTIONATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIFE EXPECTANCY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS;

EID: 84879418486     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0410-z     Document Type: Article

References (19)

1. Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12:354-362
2. Faivre J, Forman D, Estève J, Gatta G (1998) Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 34:2167-2175
3. Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
4. Pyrhönen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
5. Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
6. Janunger KG, Hafstrom L, Nygren P et al (2001) A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40:309-326
7. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin and fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
8. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
9. Roth AD, Fazio N, Stupp R et al (2007) Docetaxel, cisplatin and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217-3223
10. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
11. Pronk L, Vasey PA, Sparreboom A et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22-29
12. Pfeiffer P, Hahn P, Jensen HA (2003) Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 42:832-836
13. Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human xenografts. Clin Cancer Res 4:1013-1019
14. See Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. (http://ctep.cancer.gov). Publication date: December 12, 2003
15. Corona G, Elia C, Casetta B et al (2011) High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 412(3-4):358-364
16. Grothe W, Hofheinz RD, Mantovani L et al. Phase I trial of docetaxel, oxaliplatin and capecitabine (TEX) in patients with metastatic gastric cancer. J Clin Oncol 2006, ASCO annual meeting proceedings, vol 24, No 18S (June 20 Supplement), 2006:1405
17. Evans D, Miner T, Akerman P et al (2007) A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 30:346-349
18. Andersen M, Schønnemann KR, Yilmaz M et al (2010) Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncol 49:1246-1252
19. Malik I, Bernal P, Byrd J (2010) A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. Cancer Invest 28:833-838